Education
About Us
Working with TipRanks
Follow Us
Palvella Therapeutics (PVLA)
NASDAQ:PVLA
PVLA Stock Chart & Stats
$99.73
-$0.34(-2.31%)
At close: 4:00 PM EST
$99.73
-$0.34(-2.31%)
Day’s Range― - ―
52-Week Range$12.10 - $114.69
Previous CloseN/A
Volume11.83K
Average Volume (3M)254.47K
Market Cap
$1.18B
Enterprise Value$646.07M
Total Cash (Recent Filing)$63.57M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.03
Next Earnings
Apr 06, 2026EPS Estimate
-0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding11,836,490
10 Day Avg. Volume210,890
30 Day Avg. Volume254,465
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.43
Price to Sales (P/S)0.00
P/FCF Ratio-2.46
Enterprise Value/Market Cap0.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-33.81
Forecast
1Y Price Target
$181.64Price Target Upside82.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-3.96
Revenue Forecast (FY)$28.57K
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 2 data showed a high proportion of patients treated with the topical rapamycin candidate experienced clear clinical improvement, supporting the therapy's disease‑modifying potential in targeted skin disorders.
Commercial Adoption PotentialPhysician market research indicates strong willingness to adopt a high‑concentration topical mTOR inhibitor or a topical mevalonate pathway inhibitor as first‑line therapy for relevant skin conditions, suggesting meaningful uptake if approved.
Regulatory EngagementCompany plans to meet with the FDA to align on trial design and to initiate the next pivotal study after completing required enabling work, which supports disciplined clinical development progress.
Bears Say
Cash RunwaySignificant cash burn and a limited cash runway create funding risk that may force the company to seek additional capital and could dilute existing shareholders or delay programs.
Development Execution RiskAdvancement to later‑stage trials depends on successful completion of enabling studies and regulatory alignment, introducing execution risk that could slow development timelines if issues arise.
Market Sentiment VolatilityRecent share weakness appears driven by a sell‑the‑news market reaction rather than fundamentals, increasing near‑term volatility and potentially obscuring underlying clinical progress.
Palvella Therapeutics News
PVLA FAQ
What was Palvella Therapeutics’s price range in the past 12 months?
Palvella Therapeutics lowest stock price was $12.10 and its highest was $114.69 in the past 12 months.
What is Palvella Therapeutics’s market cap?
Palvella Therapeutics’s market cap is $1.18B.
When is Palvella Therapeutics’s upcoming earnings report date?
Palvella Therapeutics’s upcoming earnings report date is Apr 06, 2026 which is in 78 days.
How were Palvella Therapeutics’s earnings last quarter?
Palvella Therapeutics released its earnings results on Nov 11, 2025. The company reported -$1.03 earnings per share for the quarter, missing the consensus estimate of -$0.838 by -$0.192.
Is Palvella Therapeutics overvalued?
According to Wall Street analysts Palvella Therapeutics’s price is currently Undervalued.
Does Palvella Therapeutics pay dividends?
Palvella Therapeutics does not currently pay dividends.
What is Palvella Therapeutics’s EPS estimate?
Palvella Therapeutics’s EPS estimate is -0.91.
How many shares outstanding does Palvella Therapeutics have?
Palvella Therapeutics has 11,836,490 shares outstanding.
What happened to Palvella Therapeutics’s price movement after its last earnings report?
Palvella Therapeutics reported an EPS of -$1.03 in its last earnings report, missing expectations of -$0.838. Following the earnings report the stock price went down -3.039%.
Which hedge fund is a major shareholder of Palvella Therapeutics?
Currently, no hedge funds are holding shares in PVLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Palvella Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$181.64 (82.13% Upside)
$181.64 (82.13% Upside)
Blogger Sentiment
Bullish
PVLA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 252.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▲ 31.6%
Last 30 Days ▲ 31.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
654.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
226.17%
Trailing 12-Months
Company Description
Palvella Therapeutics
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
PVLA Company Deck
PVLA Earnings Call
Q3 2025
0:00 / 0:00
PVLA Stock 12 Month Forecast
Average Price Target
$181.64
▲(82.13% Upside)
Technical Analysis
Theravance Biopharma
―
Monopar Therapeutics Inc
―
Nurix Therapeutics
―
Terns Pharmaceuticals
―
Tyra Bioscience
―
Ownership Overview
1.83% Insiders
5.71% Mutual Funds
45.35% Other Institutional Investors
37.53% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---